CWT 002
Alternative Names: CWT-002; OsteoMiR™Latest Information Update: 07 Sep 2023
At a glance
- Originator Causeway Therapeutics
- Class MicroRNAs; Skin disorder therapies
- Mechanism of Action MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin aging
Most Recent Events
- 12 Jul 2023 Discontinued for Intervertebral disc degeneration in United Kingdom (Injection) (Causeway Therapeutics pipeline, July 2023)
- 12 Jul 2023 Discontinued for Osteoarthritis in United Kingdom (Injection) (Causeway Therapeutics pipeline, July 2023)
- 03 Jul 2023 Early research in Skin aging in USA (Injection) (Causeway Therapeutics pipeline, July 2023)